Outcome of COVID-19: Diabetes and Obesity
Journal of Pharmaceutical Research International · pp. 248–255 · Published 15 Dec 2021
10.9734/jpri/2021/v33i58A34113Abstract
Today the world is facing one of the biggest crisis, due to a new beta-corona virus emerged from Wuhan in China, on December 2019. WHO declared ‘acute respiratory syndrome COVID-19 (SARS Co-2)’as a pandemic on March 12, 2020. Corona viruses are enveloped positive single stranded RNA viruses, causing severe acute respiratory syndrome in the infected individuals. The risk of getting infected by covid-19 is similar in all the individuals across the nation. But the outcome of the infection varies from one individual to another, depending on the comorbidities present in them. The most vulnerable group of patients in respect to severity of outcome of the infection are the once with unbalanced heath conditions like age (>65 years), immune-compromised, hypertension, type 2 diabetes, increased insulin resistance, cardiovascular diseases, chronic kidney disease, chronic liver disease, vasculitis(vascular inflammation)and obesity. It is now a public knowledge that diabetes and obesity are a risk factor for any individual as these conditions can exacerbate the manifestations of COVID-19 infections thus increasing the severity of the condition, that may require hospitalization of the patient, later may even require intensive care unit or/and mechanical ventilation, with increased risk of mortality rates. In diabetic patients it is mainly due to failure in controlling the glucose levels and the risk of ketoacidosis. In patients with obesity lipid peroxidase creates reactive lipid aldehydes leading to poor prognosis.
Cited by 23
Rajesh D. Bhoyar, Sarika Khadse, Pratiksha Munjewar · Journal of Pharmaceutical Negative Results · 2022
S. Bhoyar, S. More · Journal of Pharmaceutical Negative Results · 2022
Amit Bobade, Dipali Ghungrud, I. Alwadkar · Journal of Pharmaceutical Negative Results · 2022
Gayatri Khond, Dipali Ghungrud, Indu Alwadkar · Journal of Pharmaceutical Negative Results · 2022
Sakshi J. Patil, Pema Chuki, Bhushan Petkar · Journal of Pharmaceutical Negative Results · 2022
Prajkta Raut, S. Kolhe, Pratiksha Munjewar · Journal of Pharmaceutical Negative Results · 2022
Rohini Kakde, Prachi Kamble, Nishant Kate · Journal of Pharmaceutical Negative Results · 2022
Bhagyashri K. Pohane, Shakib H. Sheikh, Pratiksha Munjewar · Journal of Pharmaceutical Negative Results · 2022
Kranti Dehade, Shabanam N. Sheikh, Pratiksha Munjewar · Journal of Pharmaceutical Negative Results · 2022
S. Kolhe, Pratiksha Munjewar, Aniket Pathade · Journal of Pharmaceutical Negative Results · 2022
Showing 22 of 23 known citations — external sources report more than can currently be individually listed.
Related research
- Metabolic Syndrome among Healthcare Workers in a Tertiary Hospital in South-South, Nigeria — shares topic coverage
- Dietary Pattern and Prevalence of High Blood Pressure among Adult Traders in Port Harcourt, Nigeria — shares topic coverage
- Impact of the Diet Profile and Alcohol Consumption on Cardiometabolic Risks in Dschang Health District-Cameroon — shares topic coverage
- Gender Specific Predictive Performance and Optimal Threshold of Anthropometric Indices for the Prediction of Hypertension among a Ghanaian Population in Kumasi — shares topic coverage
- Metabolic Syndrome and Kidney Damage: Prevalence and Assessment of Risk among Apparently Healthy Resident of Ado Ekiti, South West Nigeria — shares topic coverage
Article metrics
Real usage data collected on this platform.
2
Page views
0
PDF downloads
0
Outbound clicks
23
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.